先天性肾上腺皮质增生症治疗市场
先天性肾上腺皮质增生症治疗市场：2026年市场规模约为4.4638亿美元，2031年市场规模约为6.1909亿美元；预测期复合年增长率为6.76%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
先天性肾上腺皮质增生症治疗市场：2026年市场规模约为4.4638亿美元，2031年市场规模约为6.1909亿美元；预测期复合年增长率为6.76%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 6.76% | 机构预测 |
| 市场规模 | 2026 | USD 446.38 million | 机构预测 |
| 市场规模 | 2031 | USD 619.09 million | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease_type | classic congenital adrenal hyperplasia | 2025 | 69.310% |
| distribution_channel | hospital pharmacies | 2025 | 48.650% |
| drug_class | glucocorticoids | 2025 | 60.240% |
| geography | North America | 2025 | 46.610% |
| route_of_administration | oral formulations | 2025 | 88.640% |
关键结论
- disease_type 维度中，classic congenital adrenal hyperplasia 在 2025 年的公开份额为 69.31%。
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 48.65%。
- drug_class 维度中，glucocorticoids 在 2025 年的公开份额为 60.24%。
- geography 维度中，North America 在 2025 年的公开份额为 46.61%。
- route_of_administration 维度中，oral formulations 在 2025 年的公开份额为 88.64%。
主要参与者
- Neurocrine Biosciences, Inc.
- Eton Pharmaceuticals, Inc.
- Spruce Biosciences, Inc.
- Crinetics Pharmaceuticals, Inc.
- BridgeBio Pharma, Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Expansion of Newborn Screening Programs | +1.800% | Global | Medium term (2-4 years) |
| Approval of a Nonsteroidal Adjunctive Therapy | +2.200% | North America with anticipated global label expansion | Short term (≤ 2 years) |
| Demand for Physiological Glucocorticoid Replacement | +1.400% | North America and Europe | Medium term (2-4 years) |
| Increasing Use of Genetic and Steroid Profiling | +0.900% | North America and Europe, expanding to Asia-Pacific | Medium term (2-4 years) |
| Asia-Pacific Specialty-Care Expansion | +1.000% | Asia-Pacific core, with spillover to Middle East and Africa | Long term (≥ 4 years) |
| Patient Registry and Real-World Evidence Development | +0.600% | Global | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Lifelong Cost Burden of Hormone Replacement | -0.700% | Global | Short term (≤ 2 years) |
| Narrow Therapeutic Window for Glucocorticoid Dosing | -0.600% | Global | Medium term (2-4 years) |
| Limited Availability of Specialized Endocrine Monitoring | -0.500% | Asia-Pacific, Middle East and Africa, and South America | Long term (≥ 4 years) |
| Slow Adoption of Modified-Release and Novel Therapies | -0.400% | Global except North America | Medium term (2-4 years) |
报告关注的关键问题
What is driving growth in congenital adrenal hyperplasia treatment?
The congenital adrenal hyperplasia treatment market is expected to grow from USD 446.38 million in 2026 to USD 619.09 million by 2031, registering a CAGR of 6.76% during the forecast period (2026–2031).
Which treatment class is growing fastest for congenital adrenal hyperplasia?
CRF1 and ACTH pathway inhibitors are forecast to grow at a 10.22% CAGR through 2031, led by crinecerfont and the advancement of atumelnant.
Why are glucocorticoids still important in CAH care?
Glucocorticoids accounted for 60.24% of revenue in 2025 because cortisol replacement remains necessary for long-term disease management.
Which region is growing fastest for congenital adrenal hyperplasia treatment?
Asia-Pacific is forecast to grow at an 8.25% CAGR through 2031 as specialist care, screening, and rare-disease development programs expand.
What role do specialty pharmacies play in CAH therapy?
Online and specialty pharmacies are forecast to grow at a 9.95% CAGR because they support dispensing, reimbursement navigation, adherence monitoring, and patient assistance.
What are the main barriers to wider adoption of newer CAH treatments?
Lifelong cost, reimbursement delays, demanding dose adjustment, and limited access to specialist monitoring can slow uptake outside major care centers.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence